focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,148.00
Bid: 12,146.00
Ask: 12,150.00
Change: -24.00 (-0.20%)
Spread: 4.00 (0.033%)
Open: 12,180.00
High: 12,198.00
Low: 12,076.00
Prev. Close: 12,172.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

German state would back production of Russia's Sputnik V vaccine

Thu, 04th Feb 2021 13:54

BERLIN, Feb 4 (Reuters) - Germany, keen to speed up
vaccinations against the coronavirus, could back local vaccine
maker IDT Biologika by expediting approval for production if it
chose to help manufacture the Russian COVID-19 shot, a regional
official said on Thursday.

IDT Biologika, based in Dessau-Rosslau in eastern Germany,
produces viral vaccines for pharmaceutical companies including
the coronavirus shot developed by AstraZeneca's with
Oxford University.

"If IDT Biologika wants to produce the Russian vaccine and
it would be approved in the EU, we as a state government would
of course do everything to help the company," a spokesman for
the state of Saxony-Anhalt said.

This could include fast-tracking the approval process as has
happened in the states of North Rhine-Westphalia and Hesse for
manufacturing capacity for BioNTech's and Pfizer's
vaccine, he said.

"There are no ideological reservations against Sputnik V. We
welcome anything that can help in the fight against corona."

Germany and other European Union governments are under fire
over a slow start to vaccinations in the EU. Critics point to
faster progress made in Britain, Israel and the United States as
evidence of a planning failure in Brussels and elsewhere.

Russian scientists gave Russia's Sputnik V vaccine the green
light on Tuesday, saying it was almost 92% effective in fighting
COVID-19 based on peer-reviewed, late-stage trial results
published in The Lancet international medical journal.

IDT declined to say whether it had been approached by
Russian developers. "We are in negotiations with various vaccine
manufacturers to jointly meet the major challenge of reliable
vaccine supply," a spokeswoman said, adding the company could
not provide information on current requests.

The German government has blamed the halting pace of
vaccinations, and a squeeze on supplies of the shots, on cuts to
deliveries from vaccine makers AstraZeneca, Pfizer and
Moderna.

Germany has said it would use Sputnik V if it is approved by
the EU's drug regulator, and Chancellor Angela Merkel has said
German regulator, the Paul-Ehrlich Institute, could help guide
Russia through the EU approval process.
(Reporting by Andreas Rinke and Ludwig Burger
Writing by Caroline Copley
Editing by Mark Heinrich)

More News
13 Feb 2024 12:06

LONDON MARKET MIDDAY: Stocks fall but pound up before US data

(Alliance News) - Stock prices in London were on the decline on Tuesday afternoon, with sentiment tetchy ahead of a US inflation report later.

Read more
13 Feb 2024 09:32

LONDON BROKER RATINGS: Citi lifts GSK; Shore likes XPS Pensions

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
12 Feb 2024 12:04

LONDON MARKET MIDDAY: FTSE 100 underperforms as European peers rise

(Alliance News) - London's FTSE 100 underwhelmed on Monday, with some of its largest constituents pulling it lower, while indices in Europe were on the up on favourable comments on interest rate cuts by a European Central Bank official.

Read more
12 Feb 2024 09:41

LONDON BROKER RATINGS: Deutsche Bank starts Deliveroo at 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
12 Feb 2024 09:12

Barclays sees "compelling" entry point at AstraZeneca after recent falls

(Sharecast News) - Barclays has kept an 'overweight' position on AstraZeneca despite the biopharma group's disappointing annual results last week, saying that the stock's recent underperformance provides an attractive entry point for investors.

Read more
9 Feb 2024 09:15

LONDON BROKER RATINGS: Deutsche Bank cuts AstraZeneca to 'sell'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
9 Feb 2024 07:51

LONDON BRIEFING: Barclays buys Tesco's retail banking business

(Alliance News) - Stocks in London are called to open higher on Friday, closing off a busy corporate week.

Read more
8 Feb 2024 17:00

LONDON MARKET CLOSE: Softer earnings weigh on underperforming FTSE 100

(Alliance News) - London's FTSE 100 ended lower on Thursday, with mixed corporate updates keeping a lid on enthusiasm, while in New York the S&P 500 has the 5,000 point mark in touching distance.

Read more
8 Feb 2024 14:42

London close: Stocks slip as US jobless claims fall

(Sharecast News) - London markets experienced a downturn in trading on Thursday, with stocks relinquishing earlier gains as investors processed a decrease in jobless claims in the United States.

Read more
8 Feb 2024 12:08

LONDON MARKET MIDDAY: DS Smith surges on takeover approach from Mondi

(Alliance News) - Stock prices in London were mixed at midday Thursday, as markets struggled to find direction amid a mixed wave of corporate updates and earnings.

Read more
8 Feb 2024 08:59

LONDON MARKET OPEN: Unilever up on buyback; BAT ups dividend

(Alliance News) - THE FTSE 100 in London opened slightly higher on Thursday, with earnings from British American Tobacco and Unilever boosting the index.

Read more
8 Feb 2024 08:44

TOP NEWS: AstraZeneca confident after 2023 profit more than doubles

(Alliance News) - AstraZeneca PLC on Thursday said it expects another year of strong growth after reporting pretax profit in 2023 more than doubled.

Read more
8 Feb 2024 07:58

AstraZeneca shares slip as Q4 profits miss forecasts

(Sharecast News) - Biopharma titan AstraZeneca delivered a 6% increase in sales in 2023 despite a $3.7bn decline in Covid-19 medicines revenues, as it guided to a strong pick-up in growth this year - though profits came in slightly under analysts' forecasts.

Read more
8 Feb 2024 07:50

LONDON BRIEFING: Unilever sets new buyback; Astra profit surges

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye a busy day of earnings.

Read more
2 Feb 2024 08:38

AstraZeneca celebrates latest successful trial of acoramidis in Japan

(Alliance News) - AstraZeneca PLC on Friday said positive results from a Phase 3 trial of acoramidis are consistent with global findings, bring the drug closer to regulatory submission in Japan.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.